Loading company…
Lysosomal Therapeutics develops enzyme replacement and substrate reduction therapies for lysosomal storage disorders.
Founded in 2014 in Cambridge, US, Lysosomal Therapeutics develops therapies for lysosomal storage disorders, including enzyme replacement and substrate reduction therapies, mainly for North America and select European markets. The company is at the Series A stage. It has completed 4 deals and raised a total of USD 16.13 mn, with its most recent round a USD 1.00 mn Venture Debt round completed on October 25, 2019. Kees Been is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in